Antibody-drug conjugates (ADCs) represent an important class of cancer therapies that have
revolutionized the treatment paradigm of solid tumors. To date, many ongoing studies of …

Simple Summary Antibody–drug conjugates (ADC) have shown remarkable therapeutic
activity in a wide range of hematologic and solid tumors. Herein, we discuss the …

Human epidermal growth factor receptor 2 (HER2) regulates cell mitosis, proliferation, and
apoptosis. Trastuzumab is a HER2-targeted monoclonal antibody (mAB), which can prolong …

Radiotherapy (RT) is a mainstay treatment for many types of cancer, although it is still a
large challenge to enhance radiation damage to tumor tissue and reduce side effects to …

Antibody drug conjugates (ADCs) are novel medications that combine monoclonal
antibodies with cytotoxic payloads, enabling the selective delivery of potent drugs to cancer …

The Click Activated Protodrugs Against Cancer (CAPAC) platform enables the activation of
powerful cancer drugs at tumors. CAPAC utilizes a click chemistry reaction between …

Locally advanced cancers remain therapeutically challenging to eradicate. The most
successful treatments continue to combine decades old non-targeted chemotherapies with …

Human epidermal growth factor receptor 2 (HER2) belongs to the ErbB family, a group of
four transmembrane glycoproteins with tyrosine kinase activity, all structurally related to …

The research of integrin-targeted anticancer agents has recorded important advancements
in ingenious design of delivery systems, based either on the prodrug approach, or on …

Clinical treatment of cancer commonly incorporates X‐ray radiation therapy (XRT), and
develo** spatially precise radiation‐activatable drug delivery strategies may improve XRT …